Coroflex® ISAR NEO PMCF Study

Who May Qualify: Coroflex® ISAR NEO is intended to be used for - Patients must be at least 18 years of age AND - The patient must fulfill the standard recommendations for Percutaneous Coronary Intervention (PCI) based on the last European Society of Cardiology (ESC) recommendations within his/ her regular treatment or that the use of the product has already been decided within the regular planning of the patient's treatment AND - Patients with Novo lesion length 2-4 mm AND - willing to sign a consent form signed Who Should NOT Join This Trial: - Patients with express refusal by the patient to participate in the study. - Patients pregnant women and lactating women. - Patients with acute coronary syndrome (ACS) in a situation of cardiogenic shock (Killip 4). - Patients in whom anti-platelet and/or anti-coagulation therapy is contraindicated - Patients with lesions, that possibly can not be treated successfully with Percutaneous transluminal Coronary Angioplasty (PTCA) or stent implantation - Patients with known sensitivity to Sirolimus, the carrier Probucol, the procedural co-medication or the alloying component of the stent - Patients with known sensitivity to contrast agents who cannot be premedicated. - Patients with contraindications or hypersensitivity to sirolimus - Patients with a life expectancy of less than 2 years - Patients included in other clinical trials Always talk to your doctor about whether this trial is right for you.